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Moringa oleifera (M. oleifera) is an angiosperm plant, native of the Indian subcontinent,
where its various parts have been utilized throughout history as food and medicine. It is
now cultivated in all tropical and sub-tropical regions of the world. The nutritional, pro-
phylactic, and therapeutic virtues of this plant are being extolled on the Internet. Dietary
consumption of its part is therein promoted as a strategy of personal health preserva-
tion and self-medication in various diseases. The enthusiasm for the health beneﬁts of M.
oleifera is in dire contrast with the scarcity of strong experimental and clinical evidence
supporting them. Fortunately, the chasm is slowly being ﬁlled. In this article, I review cur-
rent scientiﬁc data on the corrective potential ofM. oleifera leaves in chronic hyperglycemia
and dyslipidemia, as symptoms of diabetes and cardiovascular disease (CVD) risk. Reported
studies in experimental animals and humans, although limited in number and variable in
design, seem concordant in their support for this potential. However, before M. oleifera
leaf formulations can be recommended as medication in the prevention or treatment of
diabetes and CVD, it is necessary that the scientiﬁc basis of their efﬁcacy, the therapeu-
tic modalities of their administration and their possible side effects be more rigorously
determined.
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INTRODUCTION
Moringa oleifera, Lam (M. oleifera), also known as Moringa ptery-
gosperma Gaertn, is amember of theMoringaceae family of peren-
nial angiosperm plants, which includes 12 other species (Olson,
2002). Native of the sub-Himalayan northern parts of India, it is
cultivated throughout tropical and sub-tropical areas of the world,
where it is known by various vernacular names (Ramachandran
et al., 1980), with drumstick tree, horseradish tree, and malunggay
being the most commonly found in the literature.
Moringa oleifera is an edible plant. A wide variety of nutritional
andmedicinal virtues have been attributed to its roots, bark, leaves,
ﬂowers, fruits, and seeds (Ramachandran et al., 1980; Anwar et al.,
2007; Kumar et al., 2010). Phytochemical analyses have shown
that its leaves are particularly rich in potassium, calcium, phos-
phorous, iron, vitamins A and D, essential amino acids, as well
Abbreviations: ACP, acid phosphatase; ALP, alkaline phosphatase; ALT, alanine
aminotransferase; AST, aspartate amino transferase; AUC, area under the curve;
bw, body weight; CAD, coronary artery disease; CVD, cardiovascular disease; DM,
diabetes mellitus; FPG, fasting blood glucose; GIT, gastrointestinal tract; GK, Goto-
Kakizaki; HbA1c, glycated hemoglobin; HCD, high-cholesterol diet; HDL, high-
density lipoprotein; HFD, high-fat diet; IL, interleukin; IPGTT, intraperitoneal
glucose tolerance test; LDL, low-density lipoprotein; LDLR, LDL receptor; NEFA,
non-esteriﬁed fatty acid, OGTT, oral glucose tolerance test; oxLDL, oxidized LDL;
PCSK9, proprotein convertase, subtilisin/kexin-type 9; PPPG, post-prandial blood
glucose; PVC,packed cell volume;ROS, reactive oxygen species; SREBP, sterol regula-
tory element-binding protein; STZ, streptozotocin; T2DM, type-2 diabetes mellitus;
TG, triglyceride; TNF, tumor necrosis factor; VLDL, very low-density lipoprotein;
VSMC, vascular smooth muscle cell; WBC, white-blood cell.
as such known antioxidants such as β-carotene, vitamin C, and
ﬂavonoids (Bennett et al., 2003; Aslam et al., 2005; Manguro and
Lemmen, 2007; Amaglo et al., 2010; Gowrishankar et al., 2010).
The therapeutic use of M. oleifera parts in the Indian subcon-
tinent dates back to Antiquity. In other parts of the world, in
sub-Saharan Africa in particular, such a use appears not to have
been known by the wide public, as it is being promoted by diverse
organizations as an untapped opportunity (Thurber and Fahey,
2009; Torimiro et al., 2009). At the writing of this manuscript
(April 2011), a search on the Internet, using the Google browser
and the words moringa, drumstick, or malunggay as keys within
page titles, reported nearly 90,000 websites. Most of these sites
present this plant as a remedy to malnutrition and a vast range of
ailments. On the Internet,M. oleifera is variably labeled as Miracle
Tree, Tree of Life, Mother’s Best Friend, God’s Gift to Man, Sav-
ior of the Poor. In many regions of Africa, it is widely consumed
for self-medication by patients affected by diabetes, hypertension,
or HIV/AIDS (Dieye et al., 2008; Kasolo et al., 2010; Monera and
Maponga, 2010). Yet, in a similar search of the PubMed database
of biomedical publications, merely 163 papers were fetched; 76%
of them were published in the last decade (Figure 1). A similar
search through Google Scholar produced about 1250 articles; the
vast majority of these were in scientiﬁc journals not indexed in
PubMed, and a good number in non-peer-reviewed book chap-
ters, patents, citations, or other documents. By comparison, green
tea, another plant claimed to be medicinal for a range of ill-
nesses (Schneider and Segre, 2009), 1972 and 7240 publications
were retrieved in a similar search in PubMed and Google Scholar,
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FIGURE 1 | Chronological trend of scientific publications on M.
oleifera.The bibliographic search was conducted online in the PubMed
database at www.pubmed.ncbi.nlm.nih.org/, using moringa, drumstick, or
malunggay as title keywords. Article abstracts were reviewed for content
and those unrelated to M. oleifera were discarded. Of the 163 PubMed
articles retained, 64 (39.3%) were about the physiological effects of M.
oleifera preparation in experimental animals, 30 (18.4%) on their
water-cleansing properties as toxic metal absorbent or ﬂocculent, 23
(14.1%) about their chemical composition, 22 (13.5%) about their
antimicrobial efﬁcacy, 5 (3.1%) about their antioxidant properties in vitro, 5
(3.1%) about their effects on cellular physiology ex vivo, 6 (3.1%) on their
nutritional values, 3 (1.8%) about their therapeutic effects in humans, and 6
about various matters (review, genetics, biofuel, animal feed).
respectively. Clearly, in spite of the widely held “belief” in the
health beneﬁts of M. oleifera, the interest of the international bio-
medical community in the medicinal potential of this plant has
been rather tepid.
This report is a review of current data on the therapeutic poten-
tial of M. oleifera in chronic hyperglycemia and dyslipidemia.
Chronic hyperglycemia is an indicator of diabetes mellitus (DM),
and chronic dyslipidemia a risk factor for cardiovascular disease
(CVD). These metabolic disorders are global epidemics (Yusuf
et al., 2001; Wild et al., 2004). In developing countries, they are on
theway to becoming asmajor causes of morbidity andmortality as
infectious diseases, due to the progressive transition in these coun-
tries to a lifestyle characterized, among other aspects, by greater
access to dietary calories and less demand for calorie expenditure
(Hossain et al., 2007; Aje and Miller, 2009). Geographically, many
of developing countries are located in the tropical and sub-tropical
regions of the world where M. oleifera grows and is cultivated. If
validated by medical science, dietary consumption of this plant
could be advocated in these and other countries as an inexpensive
prophylactic strategy against DM and CVD.
The review covers peer-reviewed studies of the therapeutic
potential of M. oleifera in these pathologies. It focuses on stud-
ies involving experimental animal models and human subjects,
in which leaves were used as the medicinal parts of the plant.
Leaves were generally administered per os (p.o.) as powders or
aqueous or organic extracts thereof, and, for experimental animals,
at body weight-adjusted doses. A therapeutic effect was deﬁned as
a beneﬁcial change in speciﬁc biochemical parameters of disease.
The review includes ﬁve sections. The ﬁrst two sections are con-
cernedwith the scientiﬁc evidence of M. oleifera efﬁcacy at correct-
ing chronic hyperglycemia or dyslipidemia. They each begin with
a brief description of main aspects of glucose or lipid homeostasis
and its pathogenic disruption, so that the therapeutic efﬁcacy of
the plant could be subsequently evaluated based on current bio-
medical understanding. The third section attempts to correlate
the observed therapeutic effects with the presence in the leaves
of physiological properties or chemical constituents experimen-
tally proven to offer such metabolic beneﬁts. The fourth section
brieﬂy examines what is known of the possible toxicity of M.
oleifera leaves. The ﬁnal section identiﬁes obvious gaps in current
knowledge andproposes potential avenues for future investigation.
METHODOLOGY
Two biomedical literature databases were searched: PubMed and
Google Scholar (subsections: Biology, Life Science, Environmen-
tal Science,Medicine, Pharmacology, andVeterinary Science). The
search was conducted using moringa or drumstick as a keyword
within the title of the article. Articles dealing with Moringa vari-
eties other than oleifera were excluded; as were articles in which
the word drumstick referred to other subject matters (e.g.,medical
conditions or transcription factor) than the plant. All the remain-
ing articles, including reviews, were critically read. Peer-reviewed
articles presenting results of experimental studies, in animals or
humans, on the therapeutic potential of M. oleifera leaf extract
or powder in chronic hyperglycemia or hyperlipidemia were ana-
lyzed for inclusion in this review. The analysis focused on therapy
subjects, galenic formulation, mode of administration, dosage,
treatment duration, and measurable biochemical outcomes.
THERAPEUTIC POTENTIAL OF M. OLEIFERA IN CHRONIC
HYPERGLYCEMIA
GLUCOSE HOMEOSTASIS
Glucose is a major fuel for animal cells. It is supplied to the organ-
ism through dietary carbohydrates and, endogenously, through
hepatic gluconeogenesis and glycogenolysis. Glucose absorption
from the gastrointestinal tract (GIT) into blood is regulated by a
variety of neuronal signals and enterohormones (incretins), aswell
as bymeal composition and the intestinal ﬂora.Glucosehomeosta-
sis reﬂects a balance between glucose supply and its utilization.
Physiologically, this balance is determined by the level of circulat-
ing insulin and tissue responsiveness to it. Insulin is secreted by
pancreatic islet β cells. It stimulates glucose uptake and utilization
by tissues, especially by liver, skeletal muscle, and adipose tissue. It
also suppresses gluconeogenesis in hepatocytes, while stimulating
lipogenesis and inhibiting lipolysis in adipocytes (Gerich, 2000).
HYPERGLYCEMIA
An individual is diagnosed as diabetic when his blood glucose level
is chronically≥126mg/dL after anovernight fast, and≥200mg/dL
2 h after an oral glucose load of 75 g (oral glucose tolerance test,
OGTT; Alberti and Zimmet, 1998). Age, genetics, environment,
and lifestyle inﬂuence the development of this pathology. The rela-
tive importance of these factors and their combinatorial effects are
not yet fully understood. Two types of DM are commonly recog-
nized: type 1 DM (T1DM) results from autoimmune destruction
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of pancreatic β cells and represents only 5% of all cases; type-2
DM (T2DM) is the most common form of the disease and the
primary concern of this review.
In its early stages, T2DM is characterized by chronic hyper-
glycemia and hyperinsulinemia, due to loss of tissue sensitivity to
insulin,and compensatory secretionof thehormoneby isletβ cells.
Its progression involves a complex network of interacting cellular
and physiological alterations leading to β cell failure. Glucotoxicity
and lipotoxicity are the most commonly invoked mechanisms for
this failure (Robertson et al., 2004).
Glucotoxicity arises from excessive uptake of glucose by islet β
cells. The excess sugar drives glycation reactions and the mito-
chondrial electron transport chain, producing macromolecule-
damaging reactive oxygen species (ROS), at levels beyond the
antioxidation capacity of the cell. The ensuing oxidative stress
impairs insulin synthesis and secretion, and initiates a cascade
of cellular events that ultimately lead to apoptosis (Kaneto et al.,
2007).
Lipotoxicity, on the other hand, results in part from the unre-
sponsiveness of adipocytes to insulin, negating the ability of this
hormone to stimulate uptake by these cells of non-esteriﬁed fatty
acids (NEFA) that result from triglycerides (TG) lipolysis in cir-
culation, and to inhibit lipolysis of endogenous TG to NEFA.
Excess plasmaNEFA impairs insulin secretion by β cells, stimulates
gluconeogenesis by liver, and inhibits glucose disposal by skele-
tal muscle, further exacerbating hyperglycemia (Stumvoll et al.,
2005). NEFA accumulation in the bloodstream is further aggra-
vated by obesity, a condition characterized by an expanded adipose
mass. Furthermore,adipose tissues, especially the visceral anddeep
subcutaneous ones, secrete pro-inﬂammatory cytokines such as
interleukin 6 (IL-6) and tumor necrosis factor α (TNFα), which
also contribute to tissue insensitivity to insulin.
Impaired TG storage into adipocytes facilitates the forma-
tion in the bloodstream of small, cholesterol ester-poor, TG-rich
low-density lipoprotein (LDL) particles. Hyperglycemia promotes
glycation of these particles, a modiﬁcation that extends their
half-life in circulation. These particles are prone to oxidation and
are potent initiators of atherogenesis and its vascular damages
(discussed in more detail below). Diabetes-associated neuropathy,
retinopathy, and nephropathy are some of the consequences of
these damages (Dokken, 2008).
Underlying these complex physiological changes are mole-
cular alterations in the relative levels of expression and post-
translational modiﬁcations of a wide variety of gene products,
including surface receptors, second messengers and transcrip-
tional factors.
EVIDENCE OF ANTI-HYPERGLYCEMIC PROPERTIES OF M. OLEIFERA
Moringa oleifera parts have been used in folk medicine for the
treatment of diabetes (Dieye et al., 2008). Five studies aimed at ver-
ifying these properties using leaves were identiﬁed in the scientiﬁc
literature: two were conducted in experimental animals (Ndong
et al., 2007b; Jaiswal et al., 2009) and three in T2DM patients
(William et al., 1993; Kumari, 2010; Ghiridhari et al., 2011). They
are summarized in Table 1.
Animal studies
In the study by Ndong et al. (2007b), Goto-Kakizaki (GK) Wistar
rats were used as model of DM. GK rats spontaneously develop
early glucose intolerance associated with impaired insulin secre-
tion (Bisbis et al., 1993; Abdel-Halim et al., 1995). In an OGTT,
overnight fasted Wistar controls or GK male rats were given 2 g/kg
of body weight (kg-bw) glucose by oral gavage, without or with
200mg/kg-bw of M. oleifera leaf powder. To determine blood glu-
cose levels, vein blood was collected before gavage and at different
times afterward up to 120min. Areas under the curves (AUC)
were derived from the time courses of these levels. In the absence
of treatment, fasting plasma glucose levels (FPG) and their post-
prandial levels (PPPG) at 120min were greater (∼1.4× and 2.2×,
respectively) in GK rats than in control rats. Treatment with M.
oleifera leaf powder resulted in a lower glycemic response in GK
and control rats. However, in GK rats, the treatment reduced
Table 1 | Moringa oleifera experimental therapy for chronic hyperglycemia.
A. ANIMAL MODELS
Species Inducer Plant part (extract) Protocola Corrective outcomes Reference
Rat STZ Leaf (water) 100–300mg/kg-bw; p.o., single dose; 8 h ↓FPG; ↑glucose tolerance
(OGTT)
Jaiswal et al. (2009)
Rat (GK) – Leaf 200mg/kg-bw; p.o., single dose; 2 h ↑glucose tolerance (OGTT);
↑stomach content
Ndong et al. (2007b)
B. HUMANT2DM PATIENTS (FPG>9mmol/L)
Exper. N Contr. N Plant part (formulation) Protocol Corrective outcomes
(in the experimental group)
Reference
6 6 Leaf (meal) 50 g/meal; p.o. single; 1 or 2 h ↓PPPG/FPG William et al. (1993)
46 9 Leaf (tablet) 8 g/day; p.o., daily; 40 days ↓FPG; ↓PPPG Kumari (2010)
30 30 Leaf (tablet) 2 tablets/day; p.o., daily; 1, 2, 3months ↓HbA1c; ↓PPPG Ghiridhari et al. (2011)
Exper. N, number of subjects in the experimental (treated) group; Contr. N, number of subjects in the control (untreated) group.The other abbreviations are explained
in the text.
aThe protocol brief description is given in three lines: line 1, dose; line 2, mode of administration and frequency; line 2, duration of treatment before assessment.
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AUC values by 23% (P < 0.05); it did not signiﬁcantly affect
these values in control rats. These observations suggested that M.
oleifera treatment improves plasma glucose disposal only in the
diabetic rats.
In the study by Jaiswal et al. (2009), prediabetes and diabetes
were induced in Wistar rats by intraperitoneal (i.p.) injection
of 55mg/kg-bw of streptozotocin (STZ), a cytotoxic drug that
selectively destroys islet β cells (Like and Rossini, 1976). Based
on FPG (mg/dL), STZ-treated rats were classiﬁed as sub-diabetic
(∼88mg/dL), mildly diabetic (∼190mg/dL), and severely dia-
betic (∼300mg/dL). A M. oleifera aqueous extract was admin-
istered to overnight fasted animals by oral gavage, at 100, 200, or
300mg/kg-bw. FPG was determined before treatment (baseline)
and at various time points post-treatment. An OGTT was con-
ducted 90min after the last time point. In normal rats, M. oleifera
treatment lowered FPG at all doses in time- and concentration-
dependentmanners. Six hours after administration,200mg/kg-bw
of M. oleifera extracts lowered FPG by about 26% (P < 0.05),
compared to baseline levels or the levels in untreated mice. In
an OGTT, at the same dose, a 30% fall in PPPG was observed after
3 h, in normal, sub-diabetic, and mildly diabetic rats. A 21-day
treatment of severely diabetic rats with the M. oleifera extract at
a daily dose of 300mg/kg-bw reduced FPG and PPPG by 69 and
51%, respectively, relative to untreated controls. In all the above
experiments, the hypoglycemic effect of the plant extract was com-
parable to that of the anti-diabetic drug Glipizide administered at
2.5mg/kg-bw.
Human studies
In a controlled study with untreated T2DM patients,William et al.
(1993) examined how M. oleifera addition to a standardized meal,
taken after an overnight fast, affected the 1- and 2-h PPPG, rel-
ative to the standard meal alone or a 75-g oral glucose load. M.
oleifera was compared to bitter gourd (Momordica charantia) and
curry leaves (Murraya koenigii). Compared to the glucose load,
standard meals with or without vegetable supplements induced
a signiﬁcantly lower rise in PPPG (glycemic response) as derived
from AUCs. However, when leaf-supplemented meals were com-
pared to standard meals, only the M. oleifera leaf-supplemented
meal elicited a lower response (−21%, P < 0.01). Plasma insulin
AUCsdidnot differ signiﬁcantly between the twomeals, suggesting
that the hypoglycemic effect of M. oleifera leaf supplementation
was not due to increased insulin secretion.
Kumari (2010) examined the hypoglycemic effect of M. oleifera
leaf dietary consumption over a 40-day period in T2DM patients,
30–60 years of age, not on anti-hyperglycemic medication. The
experimental group included 46 subjects, 32 men, and 14 women;
the control group of 9 subjects included 4men and 5women.Daily
meals were comparable among these groups in terms of relative
content of food types (e.g., cereals, green leafy vegetables, fruits,
etc.) and nutrients (e.g., proteins, fat, ﬁber, minerals, etc.) as well
as calories. The experimental group received a daily dose of 8 g
M. oleifera leaf powder. FPG and PPPG at the end of the protocol
(ﬁnal) were compared to baseline levels. Final values did not differ
much from baseline in the control group. They were signiﬁcantly
reduced in the experimental group (FPG: −28%, P < 0.01; PPPG:
−26%, P < 0.05).
More recently, Ghiridhari et al. (2011) studied a group of 60
T2DM patients, age 40–58 years, BMI 20–25 kg/m2, on sulfony-
lurea medication and a standardized calorie-restricted diet. The
patients were equally divided into an experimental and a control
groups. Patients in the experimental group were prescribed two
M. oleifera leaf tablets/day, one after breakfast, the other after din-
ner for 90 days. M. oleifera leaf powder constituted 98% (w/w)
of the tablet content, but the average weight of tablets was not
speciﬁed, making the total daily dose unclear. Blood glycated
hemoglobin (HbA1c) was measured before and after the regi-
men. PPPG was determined before the regimen and every 30 days
afterward. In the control group, HbA1c and PPPG progressed
downwardly with time, but the change was not signiﬁcant. In the
experimental group, in contrast, relative to the baseline, HbA1c
decreased by 0.4% point (from 7.8± 0.5 to 7.4± 0.6; P< 0.01).
Compared to the starting levels (210± 49mg/dL), PPPG in the
experimental group progressively decreased with treatment dura-
tion, by 9% after 30 days, 17% after 60 days, and 29% after
90 days (P< 0.01), indicating that M. oleifera medication can
induce with time better glucose tolerance. However, it should
be noted that treatment allocation to patients appear to have
not been randomized as baseline values for the two parameters
were higher in the experimental group than in the control group,
7.8± 0.5 vs. 7.4± 0.6% for HbA1c, 210± 49 vs. 179± 36mg/dL
for PPPG.
THERAPEUTIC POTENTIAL OF M. OLEIFERA IN DYSLIPIDEMIA
LIPID HOMEOSTASIS
Lipids constitute a major class of hydrophobic constituents of the
body. Their main forms are cholesterol, phospholipids (PL), and
triglycerides (TG). Lipids are involved in a variety of biologi-
cal processes, including membrane formation, intracellular and
intercellular signaling, as well as energy storage and production.
The body derives its lipids from de novo cellular biosynthesis and
from nutrition. Cellular biosynthesis of lipids is regulated at the
transcriptional level by sterol-regulated element-binding proteins
(SREBPs) 1 and 2. SREBP-1 promotes the biosynthesis fatty acids
and TG, SREBP-2 that of cholesterol (Horton, 2002).
Intestinal andplasma lipids are transportedby lipoproteins par-
ticles. Apolipoproteins (Apo) constitute the protein components
of these particles. Lipoproteins vary in density and, depending on
their relative contents in TG, cholesterol, and PL, are identiﬁed as
chylomicrons, very low-density lipoprotein (VLDL), LDL, inter-
mediate density lipoprotein (IDL), and high-density lipoprotein
(HDL). Lipids are transported by chylomicrons in the intestinal
lymphatic system; and, in the bloodstream, by chylomicron rem-
nants, VLDL, LDL, IDL, and HDL (Abeles et al., 1992; Havel and
Kane, 2001).
The liver plays a pivotal role in lipid metabolism. It extracts
cholesterol from intestinal chylomicrons and excretes it back into
the intestines with bile acids. It biosynthesizes TG and cholesterol
and packages them as VLDL, that it secretes into the bloodstream.
Through the LDL receptor (LDLR), it clears up plasma LDL as
well as IDL from VLDL or HDL catabolism. HDL mediates the
reverse transport of cholesterol from extra-hepatic tissues to the
liver (Havel and Kane, 2001). Liver LDLR levels and its capacity
to clear blood LDL are down-regulated by proprotein convertase
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subtilisin/kexin-type 9 (PCSK9), a plasma protein secreted by this
organ (Horton et al., 2009).
DYSLIPIDEMIA
Dyslipidemia is a disorder characterized by alterations in the levels
and composition of plasma lipids. According to Adult Treatment
Panel III (2001), plasma levels ≥200mg/dL for TC, ≥130mg/dL
for LDL-C, <40mg/dL for HDL-C, and ≥150mg/dL for TG are
dyslipidemic. Dyslipidemia may result from inborn defects of
lipoprotein production or metabolism; but in most cases, it is
secondary to an unhealthy lifestyle (e.g., excessive cigarette smok-
ing or alcohol consumption), other health disorders (e.g., obesity,
diabetes, infection, obstructive liver disease), or medication (e.g.,
β blockers, steroids).
Besides hypertension, chronic dyslipidemia is a major cause of
atherosclerosis, a vascular disease affecting blood circulation in
the coronary, central, and peripheral arteries. The pathology is
initiated by irritation of the arterial endothelium by high level of
circulating LDL-C, which leads to overexpression of adhesion and
chemoattraction molecules (e.g., vascular cell adhesion molecule-
1, intercellular adhesion molecule, P and E selectins, monocyte
chemoattractant protein-1) to injured sites, and the recruitment
and capture of circulatingmonocytes to these sites. These immune
cells penetrate into the sub endothelium and differentiate into
tissue macrophages, which take up oxidized LDL (oxLDL) via
scavenger receptors (e.g., CD36, scavenger receptor-A), becoming
the lipid-laden foam cells characteristic of atheromatous plaques.
In response to growth factors, resident vascular smooth muscle
cells (VSMC) proliferate and form a ﬁbrous cap overlying the
plaques. The oxidative process that leads to oxLDLproduction also
contributes to atherogenesis, as this modiﬁed lipoprotein and its
by-products (oxysterols and oxPL) act as monocyte chemoattrac-
tants and VSMC mitogens. Clinical complications of this process
include a narrowing of the arterial lumen, plaque rupture, and for-
mation of circulating thrombi. These complications could lead to
coronary artery disease (CAD), myocardial infarction, thrombo-
embolic stroke, and peripheral artery disease (Steinberg, 2002;
Libby et al., 2011).
Over the years, there has been a vigorous debate over the pre-
dictive value of plasma LDL-C level as a marker of CVD risk in
humans. An emerging view is that the level of non-HDL lipopro-
teins, also captured in the TC/HDL-C or HDL-C/non-HDL-C
ratio, may constitute a better marker, and its reduction a more
cogent measure of the efﬁcacy of anti-dyslipidemia therapies
(Sniderman et al., 2010; Manickam et al., 2011).
EVIDENCE OF ANTI-DYSLIPIDEMIC PROPERTY OF M. OLEIFERA
Five studies were identiﬁed in the scientiﬁc literature: three were
conducted with experimental animals (Ghasi et al., 2000; Chu-
mark et al., 2008; Jain et al., 2010), two with human subjects
(Kumari, 2010; Nambiar et al., 2010). They are summarized in
Table 2.
Animal studies
Chumark et al. (2008) examined the therapeutic potential of M.
oleifera leaves on dyslipidemia induced in rabbits on a high-
cholesterol (5%) diet (HCD) for 12weeks. By the end of the
regimen, relative to rabbits on a normal diet, HCD-fed rabbits
experienced several-fold (×) increases in the plasma levels of total
cholesterol (TC, 55×), HDL-C (17×), LDL-C (131×), and TG
(4×). The diet also caused extensive plaque formation in carotid
arteries. When these HCD rabbits were concomitantly fed a M.
oleifera aqueous leaf extract, at the daily dose of 100mg/kg-bw
for the duration of the protocol, these increases were reduced: for
TC and lipoprotein-cholesterol by about 50%, for TG by 75%,
and for carotic plaque formation by 97%. This protective effect
was comparable to that of the anti-cholesterol drug simvastatin,
given p.o., at a daily dose of 5mg/kg-bw. Similar results were also
obtained with HCD rabbits fed an aqueous extract of M. oleifera
fruits (Mehta et al., 2003).
Table 2 | Moringa oleifera experimental therapy for chronic hyperlipidemia.
A. ANIMAL MODELS
Species Inducer Plant part (extract) Protocola Corrective outcomes Reference
Rabbit HCD Leaf (water) 5mg/kg-bw; p.o., daily; 12weeks ↓TC; ↓LDL; ↓HDL; ↓TG;
↓carotid plaque formation
Chumark et al. (2008)
Rat HFD Leaf (water) 1 g/kg-bw; p.o., daily; 30 days ↓TC Ghasi et al. (2000)
Rat HFD Leaf (methanol) 150–600mg/kg-bw; p.o., daily; 30 days ↓TC; ↓LDL; ↑HDL; ↓VLDL;
↓TG; ↑fecal cholesterol;
↓atherogenic index
Jain et al. (2010)
B. HUMAN HYPERLIPIDEMICS (TC>180mg/dL orTG>140mg/dL)
Exper. N Contr. N Plant part (formulation) Protocol Corrective outcomes
(in the experimental group)
Reference
17 18 Leaf (tablet) 4.6 g/day; p.o., daily; 50 days ↓TC; ↑HDL-C; ↓non-HDL-C Nambiar et al. (2010)
46 9 Leaf (tablet) 8 g/day; p.o., daily; 40 days ↓TC; ↓LDL-C; ↓VLDL-C Kumari (2010)
Exper. N, number of subjects in the experimental (treated) group; Contr. N, number of subjects in the control (untreated) group.The other abbreviations are explained
in the text.
aThe protocol brief description is given in three lines: line 1, dose; line 2, mode of administration and frequency; line 2, duration of treatment before assessment.
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The anti-dyslipidemic effects of M. oleifera leaves were also
examined in rats fed a high-fat diet (HFD). In one study (Ghasi
et al., 2000), Wistar rats were fed, for 30 days, a HFD contain-
ing 16% (w/w) fat, with or without an aqueous extract of M.
oleifera leaves at a daily dose of 1 g/kg-bw. In untreated rats,
the diet caused a 30% increase in plasma TC. In treated rats,
the increase was reduced to 14%. In another study (Jain et al.,
2010), albino rats were fed, for 30 days, a HFD containing 26%
fat, with or without a methanolic extracts of M. oleifera leaves
at daily doses of 150, 300, or 600mg/kg-bw. In untreated rats,
the diet increased plasma TC (2.4×), LDL-C (7.7×), VLDL-C
(1.7×), and TG (1.6×). At the highest dose, M. oleifera treatment
reduced these increases to 1.5×, 2.2×, 1.3×, and 1.3×, respec-
tively (P < 0.01). Interestingly, serum HDL-C was unchanged
by HFD diet alone; it was increased 2.4× in rats fed leaf
extract-supplemented HFD, signiﬁcantly reducing the TC/HDL-C
ratio.
Human studies
Nambiar et al. (2010) examined the potential anti-dyslipidemic
effect ofM.oleifera in 35hyperlipidemic subjects (TC> 180mg/dL
or TG> 140mg/dL), 26 men and 9 women. The control and
experimental groups consisted of 18 subjects and 17 subjects,
respectively. Anthropometric values (age, height, weight, body
mass index, waist/hip ratio) within gender were similar between
the two groups, as was their daily nutrient intake. The experimen-
tal group consumed a daily total of 4.6 g of dehydrated M. oleifera
leaves, as four 550-mg tablets twice daily, for 50 days. Plasma lipid
proﬁles were determined before and after the regimen. Compared
to the control group, the experimental group experienced a 1.6%
fall in plasma TC (P < 0.05) and a 6.3% increase of HDL-C, with
non-signiﬁcant trends toward lower LDL-C, VLDL-C, and TG.
However, relative to baseline, ﬁnal non-HDL-C and TC/HDL-
C values decreased by 3.7 and 6.6%, respectively (P < 0.001),
indicating that the treatment induced a lesser atherogenic lipid
proﬁle.
In the study of T2DM patients reported by Kumari (2010),
the corrective effect of M. oleifera dietary leaves on dyslipi-
demia was also examined. Compared to the control group, the
experimental group receiving 8 g of M. oleifera leaf powder
daily for 40 days experienced a signiﬁcant fall in the plasma
levels of TC (−14%), LDL-C (−29%), VLDL-C (−15%), and
TG (−14%; P < 0.05 to <0.01). HDL-C increased by 9% (non-
signiﬁcant), but the HDL-C/non-HDL-C ratio increased by 37%
(P < 0.01).
PHARMACOLOGY OF M. OLEIFERA LEAVES
BROAD-SPECTRUM PHYSIOLOGICAL PROPERTIES
Because of the chemical complexity of the M. oleifera medicinal
formulations used in the studies reviewed above, their apparent
therapeutic effects could be due to the combined actions of var-
ious bioactive components found in the plant, including trace
metal ions, vitamins, alkaloids, carotenoids, polyphenols, fats, car-
bohydrates, and proteins (Coppin, 2008; Amaglo et al., 2010).
Some compounds may collectively affect broad aspects of physi-
ology, such as nutriment absorption and processing, redox state,
or immunity.
Anti-nutrient properties
Moringa oleifera leaves contain phytosterols such as β-sitosterol
(Jain et al., 2010). These compounds can reduce intestinal uptake
of dietary cholesterol (Lin et al., 2010). They could partly account
for the decrease of plasma cholesterol and the increase of fecal cho-
lesterol observed in rodents treated with M. oleifera leaves (Mehta
et al., 2003; Jain et al., 2010). M. oleifera leaf powder also con-
tain about 12% (w/w) ﬁbers (Joshi and Mehta, 2010). Dietary
ﬁbers reduce gastric emptying (Bortolotti et al., 2008). They may
partly explain the greater stomach content, the improved OGTT
response in treated GK diabetic rats (Ndong et al., 2007b), as well
as the progressive improvement of PPPG levels in treated T2DM
patients (Ghiridhari et al., 2011).
Antioxidant properties
The viability and functionality of a cell partly depends on a favor-
able redox state, i.e., on its ability to prevent excessive oxidation
of its macromolecules, including DNA, proteins, and lipids (Ryter
et al., 2007; Limon-Pacheco and Gonsebatt, 2009). ROS and free
radicals are the major mediators of the oxidative process. Cellu-
lar inability to reduce ROS leads to oxidative stress. All cells are
variably capable of endogenous self-protection against this stress
through the actions of enzymes such as catalase, superoxide dis-
mutase, and glutathione peroxidase, as well as through reducing
molecules such as glutathione. Nutritional antioxidants such as
vitamins A, C, and E provide additional protection from the stress
(Limon-Pacheco and Gonsebatt, 2009).
Oxidative stress is widely accepted as a major contributing fac-
tor in the pathogenesis of CVD and diabetes (Dhalla et al., 2000;
Kaneto et al., 2007; Rodrigo et al., 2011). A recurring explana-
tion for the therapeutic actions of M. oleifera medication is the
relatively high antioxidant activity of its leaves, ﬂowers, and seeds
(Chumark et al., 2008; Sreelatha and Padma, 2009; Verma et al.,
2009; Atawodi et al., 2010). Among the major classes of phyto-
chemicals found in the plant, ﬂavonoids appear to carry most of
this activity.
Anti-inﬂammatory properties
Inﬂammation with its wide array of cytokines secreted by immune
cells is an integral part of the pathophysiology of obesity, hyper-
tension, atherosclerosis, and diabetes (Rana et al., 2007). Extracts
from M. oleifera leaves have been shown to modulate humoral
and cellular immunity in rats and mice (Gupta et al., 2010; Sudha
et al., 2010). They have exhibited strong anti-inﬂammatory prop-
erties in rodent models of chemically induced inﬂammation of
the paw (Sulaiman et al., 2008; Mahajan and Mehta, 2009). These
properties have been more extensively studied with fruit and seed
extracts (Cheenpracha et al., 2010; Mahajan and Mehta, 2010;
Muangnoi et al., 2011). They may also contribute to the observed
anti-atherogenic and anti-diabetic effects of M. oleifera therapy.
BIOACTIVE PHYTOCHEMICALS
An informative historical account of research in the phytochem-
istry of M. oleifera prior to 1995 can be found in Saleem’s doctoral
thesis available on line (Saleem, 1995). Since then, the research has
been expanded and reﬁned, not only on the chemical structures
of plant molecules, but also on their nutritional and medicinal
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FIGURE 2 | Structural motifs and backbones of major phytochemicals
found M. oleifera leaves. (A) Glucosinolates and their metabolites.
(B) Flavonol major derivatives. (C) Phenolic acids. Their known derivatives
or metabolites are indicated.
properties. Of major medicinal interest are three structural classes
of phytochemicals: glucosinolates, ﬂavonoids, and phenolic acids
(Saleem, 1995; Bennett et al., 2003; Lako et al., 2007; Manguro and
Lemmen, 2007; Coppin, 2008; Amaglo et al., 2010; Kasolo et al.,
2010). Their content in M. oleifera leaves varies somewhat with
the geographic and climatic conditions under which the plant
was grown, as well as with the processing methods for the col-
lected leaves (Bennett et al., 2003; Coppin, 2008; Mukunzi et al.,
2011).
Glucosinolates are characterized by β-thioglucoside N -
hydroxysulfate motif (Figure 2A). In M. oleifera leaves, most
phytochemicals of this class carry a benzyl-glycoside group linked
to the single carbon of the motif. The most abundant of them is
4-O-(α-l-rhamnopyranosyl-oxy)-benzylglucosinolate, otherwise
known as glucomoringin (Amaglo et al., 2010). Enzymatic hydrol-
ysis of the glucosinolate motif of members of this class leads to
the formation of corresponding isothiocyanates, thiocyanates, or
nitriles. Several of these by-products have been shown to possess
antihypertensive properties (Faizi et al., 1992, 1994, 1998).
Flavonoids and phenolic acids are collectively referred to
phenolic compounds. The structural skeleton of ﬂavonoids is
made of two aromatic rings joined by a three-carbon link; that
of the sub-class of ﬂavonols is 3-hydroxy-2-phenylchromen-4-
one (Figure 2B). Quercetin and kaempferol, in their as 3′-O-
glycoside forms, are the predominant ﬂavonols in M. oleifera
leaves. The sugar moieties include, among others, rhamnogly-
cosyl (rutinosides), glucosyl (glucosides), 6′ malonyglucosyl, and
2′-galloylrutinoside groups (Bennett et al., 2003; Manguro and
Lemmen, 2007; Amaglo et al., 2010). Biologically, ﬂavonoids are
best known for their antioxidant properties, but their metabolic
pathways of activity remain to be fully elucidated (Rice-Evans,
2001). Phenolic acids have benzoic acid and cinnamic acid as
backbones, with one or several hydroxyl groups (Figure 2C).
Chlorogenic acid, which is an ester of dihydrocinnamic acid (caf-
feic acid) and quinic acid, is a major phenolic acid in M. oleifera
leaves (Bennett et al., 2003; Amaglo et al., 2010).
FIGURE 3 | Some bioactive phytochemicals found M. oleifera leaves.
Their structures were obtained from the online in the PubChem database at
www.pubmed.ncbi.nlm.nih.org/.
Four of the best-characterized phytochemicals for their thera-
peutic efﬁcacy in hyperglycemia, dyslipidemia, or related physio-
logical conditions are shown in Figure 3.
Quercetin
The ﬂavonol quercetin is found at concentrations as high as
100mg/100 g of dried M. oleifera leaves (Lako et al., 2007), pre-
dominantly as quercetin-3-O-β-d-glucoside also known as iso-
quercitrin or isotrifolin (Bennett et al., 2003; Atawodi et al.,
2010; Figure 3A). Quercetin is a potent antioxidant (Zhang et al.,
2011) with multiple therapeutic properties (Bischoff, 2008). It can
reduce hyperlipidemia and atherosclerosis inHCDorHFD rabbits
(Juzwiak et al., 2005; Kamada et al., 2005). It has shown anti-
dyslipidemic, hypotensive, and anti-diabetic effects in the obese
Zucker rat model of metabolic syndrome (Rivera et al., 2008).
It can protect insulin-producing pancreatic β cells from STZ-
induced oxidative stress and apoptosis in rats (Coskun et al., 2005).
Its hypotensive effect has been conﬁrmed in a randomized,double-
blind placebo-controlled, human study (Edwards et al., 2007).
Chlorogenic acid
Chlorogenic acid (Figure 3B) can beneﬁcially affect glucose
metabolism. It has been shown to inhibit glucose-6-phosphate
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translocase in rat liver, reducing hepatic gluconeogenesis and
glycogenolysis (Hemmerle et al., 1997; Karthikesan et al., 2010a).
It was found to lower PPBG in obese Zucker rats (Rodriguez
de Sotillo and Hadley, 2002). In OGTT experiments performed
on rats or humans, it reduced the glycemic response in both
species (van Dijk et al., 2009; Tunnicliffe et al., 2011); in rodents,
it also reduced the glucose AUC (Tunnicliffe et al., 2011). Its
anti-dyslipidemic properties are more evident as its dietary sup-
plementation has been shown to signiﬁcantly reduce plasma TC
and TG in obese Zucker rats or HFD mice (Rodriguez de Sotillo
and Hadley, 2002; Cho et al., 2010) and to reverse STZ-induced
dyslipidemia in diabetic rats (Karthikesan et al., 2010b).
Moringinine
The alkaloid moringinine was initially puriﬁed from M. oleifera
root bark (Ghosh et al., 1935) and later chemically identiﬁed as
benzylamine (Chakravarti, 1955; Figure 3C). It is also present in
leaves. This substance was suspected to mediate the hypoglycemic
effect of the plant. An early study showed thatWistar rats provided
with drinking water containing 2.9 g/L of benzylamine for 7weeks
exhibited a reduced hyperglycemic response in an intraperitoneal
glucose tolerance test (IPGTT), suggesting improved glucose tol-
erance (Bour et al., 2005). More recently, the effect was further
explored usingHFD-fed, insulin-resistant C57BL/6mice taking an
estimated daily dose 386mg/kg-bw in drinking water for 17weeks.
Compared to untreated controls, these mice gained less weight,
had reduced FPG and plasma TC, and were more glucose tolerant
(Ifﬁu-Soltesz et al., 2010).
Niaziminin
Niaziminin (Figure 3D) is a mustard oil glycoside initially isolated
(alongwith other glycosides such as niazinin and niazimicin) from
ethanolic extracts of M. oleifera leaves, based on their hypotensive
properties on Wistar rats. At 1mg and 3mg/kg-bw, these com-
pounds caused a 16–22 and a 40–65% fall of mean arterial blood
pressure (MABP), respectively (Faizi et al., 1992). Other active
isothiocyanate glycosides and thiocarbamates were isolated from
the plant using the same bioassay (Faizi et al., 1994, 1998; Saleem,
1995).
Aurantiamide acetate
This compound was isolated from M. oleifera roots and struc-
turally identiﬁed as N -benzoylphenylalanyl phenylalinol acetate
(Figure 3E). At 25μM, this unusual dipeptide derivative
inhibited by nearly 90% the secretion TNFα and IL-2 from
lipopolysaccharide-stimulated peripheral blood lymphocytes in
culture. It had no effect on IL-6 secretion (Sashidhara et al., 2009).
This inhibitory activity may contribute to the anti-inﬂammatory
properties of the plant.
TOXICOLOGY OF M. OLEIFERA THERAPY LEAVES
In the studies reviewed in this report, no acute or sub-acute toxic-
ity was reported following treatment with M. oleifera leaves at the
dosage used. The toxicology of this phytotherapy was speciﬁcally
addressed in two studies. Using rats, Adedapo et al. (2009) exam-
ined the safety of an aqueous extract of M. oleifera taken orally at
400, 800, 1600, and 2000mg/kg-bw (n = 6 rats/dose). The treat-
ment was either acute (single dose followed by a 48-h observation
period), or sub-acute (daily doses, except the highest, for 21 days
followed by hematological proﬁling). Acute treatment caused no
death at 400 or 800mg/kg-bw; it caused 1/6 and 2/6 deaths at 1600
and 2000mg/kg-bw, respectively. At these high doses, surviving
rats exhibited transient dullness for up to 5 h. Sub-acute treat-
ment with 400mg/kg-bw caused a modest (10%), but signiﬁcant
(P < 0.05) increase in packed cell volume (PCV) and white-blood
cell (WBC) count; with 800mg/kg-bw, it lowered the PCV, but
increased the WBC; with 1600mg/kg-bw, it lowered both para-
meters. The WBC changes affected lymphocytes, neutrophils, and
monocytes, but not eosinophils. Blood levels of aspartate amino-
transferase (AST), alanine aminotransferase (ALT), and alkaline
phosphatase (ALP) were also examined as surrogate indicators of
hepatic function. The resultswere inconsistent: treatmentwith 400
and 1600mg/kg-bw increasedAST andALT levels by 40–50%;with
800mg/kg-bw, it lowered it by about 50%. A 70% increase in ALP
levels was observed only after treatment with 1600mg/kg-bw. His-
tological examination of tissue sections stained with hematoxylin
and eosin revealed no alteration in testis or kidney; a diffuse tissue
degeneration was noted in liver. Interestingly, a dose-dependent
reduction of body weight gain was noted at the term of the sub-
acute treatment with M. oleifera extract: whereas untreated rats
gained 53% more weight, those treated with 400, 800, 1600mg/kg-
bw of extract gained only 37, 27, and 18%, more, respectively. It
is unclear whether this effect is symptomatic of an underlying
pathology or indicative of a potential anti-obesity property of
the plant. Considering the alterations induced by the sub-acute
treatment to be mild, the investigators concluded that nutritional
and therapeutic consumption of M. oleifera leaves at doses below
2 g/kg-bw is safe.
Other investigators have examined the effects of hexane extracts
of M. oleifera leaves on the reproductive organs of male mice after
an oral gavage at 17, 170, and 1700mg/kg-bw/day for 21 days.
They observed a dose-dependent signiﬁcant increase in testis and
epididymis weights, in seminiferous tubule diameter and in epi-
didymal epithelium thickness, but no change in the plasma levels
of gonadotropins. They concluded that these changes reﬂected
enhanced spermatogenesis (Cajuday and Pocsidio, 2010).
Several studies using experimental rodent models have shown
that M. oleifera leaf extracts can protect the liver from chemi-
cally induced damage (Pari and Kumar, 2002; Ndong et al., 2007a;
Fakurazi et al., 2008; Buraimoh, 2011).
CONCLUSION AND PERSPECTIVES
Collectively, the studies described in this review provide com-
pelling, albeit very preliminary, experimental evidence of a thera-
peutic potential of M. oleifera leaves in chronic hyperglycemia and
dyslipidemia. No report contradicting this evidence was found in
the scientiﬁc literature. A common weakness of all the human
studies reviewed herein was the fact that none was randomized
and double-blind, raising the possibilities of bias in the allocation
of patients to control and experimental groups.
In spite of converging results, a comparative analysis of these
studies is made difﬁcult by variations in agro-climatic conditions
of plant growth and harvesting, in leaf processing methods, in
ﬁnal galenic formulations, and in therapeutic protocols. The phy-
tochemical composition of M. oleifera parts have been shown to
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vary signiﬁcantly among regions and seasons (Iqbal and Bhanger,
2006; Juliani et al., 2009). Leaf extraction solvents determine the
nature and the relative concentrations of bioactive or medicinal
ingredients found in ﬁnal galenic formulations (Siddhuraju and
Becker, 2003).
Evaluation of the phytotherapy was often restricted to a nar-
row set of parameters of disease. For examples, most studies of
the anti-diabetic effects were limited to measures of FPG and
PPPG levels. Fasting and post-OGTT insulin levels were almost
never examined to verify whether the treatment improved the
ability of the endocrine pancreas to produce and secrete this hor-
mone in response to elevated blood glucose. Insulin clamp studies
would have clariﬁed whether the treatment increased tissue sensi-
tivity to the hormone. Since the medication was administered p.o.,
measures of plasma levels of incretins and other enterohormones
would have given insights on how GIT physiology is affected by
the treatment.
In the same vein, it is unclear whether the hypocholesterolemic
effect of the therapy was associated with repressed de novo cho-
lesterol biosynthesis (a statin-like effect), increased hepatic choles-
terol clearance (statin-like or anti-PCSK9-like effects) or increased
intestinal excretion. It might be interesting to ﬁnd the physiolog-
ical basis of the cardioprotective increase of the TC/non-HDL-C
ratio following treatment. A more extensive analysis on circulat-
ing biochemicalmarkers of inﬂammationwould be justiﬁed, as the
balance of pro and anti-inﬂammatory cytokines could inﬂuence
the course of both diabetes and atherosclerosis.
Besides a rationalized investigation of the therapeutic effect of
M. oleifera leaves, it is possible to conduct an unbiased search
for the affected physiological pathways. This could be achieved
by globally comparing tissues or ﬂuids of untreated and treated
animals or humans, using the powerful techniques of systems
biology, the so-called “omics” (transcriptomics, proteomics, and
metabolomics), combined with the equally powerful algorithms
of modern bioinformatics (Zhang et al., 2010).
Further exploration of the potentials and the eventual use of
M. oleifera therapy in humans will require that reference standards
be set for its cultivation, the collection of its parts, as well as for
their ﬁnal conditioning under good agricultural and collection
practices (GACP). Such guidelines, speciﬁcally directed toward
medicinal plants have been deﬁned by the WHO (2003). Further-
more,when the pharmacological basis of the therapeutic effects on
a particular pathology is rationally well circumscribed, standard-
ized assays should be required to evaluate all galenic lots for the
relevant properties. For example, on the basis of current knowl-
edge, it would indicated that the content in ﬁbers, phytosterols
as well in antioxidant and anti-inﬂammatory activities be evalu-
ated and documented in M. oleifera galenic formulations destined
to the treatment of atherosclerosis or diabetes. The shelf life of
these properties under speciﬁed storage conditions should also be
established.
In conclusion, based on the available experimental evidence,M.
oleifera leaf powder holds some therapeutic potential for chronic
hyperglycemia and hyperlipidemia. However, before it is advo-
cated in any formulation for the treatment of these metabolic
disorders in humans, state-of-the art clinical studies must be con-
ducted to establish the consistency of its medicinal efﬁcacy and
the safest modalities of its administration.
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